AAA October 2015 – Page 17

Investors prescribe $30.6m for Asceneuron

Switzerland-based drug developer Asceneuron closed a CHF 30m ($30.6m) series A round on Tuesday that included pharmaceutical firms GlaxoSmithKline (GSK), Johnson & Johnson and Merck Serono. The corporates participated through their respective investment subsdiaries SR One, Johnson & Johnson Innovation and MS Ventures. The round was led by Sofinnova Partners while Kurma Partners also participated.… Continue reading Investors prescribe $30.6m for Asceneuron